Summary
Like all fluoroquinolones, ciprofloxacin causes articular damage in juvenile animals. Consequently, this drug was not recommended for children or pregnant women. However, due to its antibacterial effectiveness and convenience of oral administration, ciprofloxacin is now increasingly used for the treatment of certain infectious conditions in children and adolescents aged less than 18 years. In this paper the published literature on this subject is reviewed. Up to now, data are available on more than 1,500 paediatric patients who were given ciprofloxacin, two-thirds of whom were suffering from acute infectious bronchopulmonary exacerbations of cystic fibrosis, mainly due toPseudomonas aeruginosa. The effectiveness of oral ciprofloxacin for this indication compared well to that of standard intravenous combination regimens. The majority of the remaining published trials was conducted in children with multiresistant typhoid fever; the administration of ciprofloxacin was successful in up to 100% of the cases. The safety profile of ciprofloxacin in children and adolescents was very similar to that observed in adult patients. Adverse events were noted in 5–15%, with gastrointestinal, skin and central nervous system reactions being the most common. Reversible arthralgia occurred in 36 out of 1,113 patients with cystic fibrosis, and in no case could cartilage damage be demonstrated by radiographic procedures. Thus, publication data clearly suggest that the administration of ciprofloxacin to children is effective and safe, but there is a need for further prospective, well-controlled clinical trials.
Zusammenfassung
Wie alle Fluorochinolone verursacht auch Ciprofloxacin Gelenkschäden bei heranwachsenden Tieren und wurde aus diesem Grund nicht zum Einsatz bei Kindern und schwangeren Frauen empfohlen. Wegen seiner antibakteriellen Wirksamkeit und der Möglichkeit einer peroralen Gabe wird die Substanz allerdings mittlerweile in steigendem Maße für die Behandlung bestimmter Infektionen bei Kindern und Jugendlichen eingesetzt. In dieser Publikation wird ein Überblick über die bisher zu diesem Thema veröffentlichte Literatur gegeben, die Daten zu mehr als 1500 pädiatrischen Patienten enthält. Zwei Drittel dieser Patienten litt an akuten infektiösen bronchopulmonalen Exazerbationen einer zystischen Fibrose, meist hervorgerufen durchPseudomonas aeruginosa. Die Wirksamkeit von Ciprofloxacin in dieser Indikation war vergleichbar mit der von etablierten intravenösen Kombinationstherapien. Die Mehrzahl der restlichen Studien wurde bei Kindern mit multiresistentem Typhus durchgeführt, bei denen eine Heilungsrate von bis zu 100% erreicht wurde. Das Sicherheitsprofil von Ciprofloxacin entsprach dem bei Erwachsenen. In 5–15% kam es zu unerwünschten Wirkungen, wobei gastrointestinale, dermale und zentralnervöse Reaktionen am häufigsten waren. Reversible Arthralgien fanden sich bei 36 von 1113 Patienten mit zystischer Fibrose; in keinem Fall zeigte sich in radiologischen Untersuchungen ein morphologisches Korrelat. Die publizierten Daten sprechen für die Wirksamkeit und Sicherheit von Ciprofloxacin auch bei pädiatrischen Patienten und belegen die Notwendigkeit weiterer, prospektiver, kontrollierter klinischer Studien.
Similar content being viewed by others
References
Ingham, B., Brentuall, D. W., Dale, E. A., McFadzean, V. A. Arthropathy induced by antibacterial fused N-alkyl-4-pyridone-3-carboxylic acids. Toxicol. Lett. 1 (1977) 21–26.
Schlüter, G. Ciprofloxacin: review of its potential toxicologic effects. Am. J. Med. 82 (Suppl. 4 A) (1987) 91–93.
Schmidt, M., Hoffmann, K. The use of quinolones in children — toxicological aspects. Adv. Antimicrob. Antineoplast Chemother. 11 (1992) 251–255.
Stahlmann, R. Knorpelschädigende Wirkung der Chinolone. Infection 19 (Suppl. 1) (1991) 38–46.
Schaad, U. B. Use of quinolones in pediatrics. Eur. J. Clin. Microbiol. Infect. Dis. 10 (1991) 355–360.
Redmond, A. O., Steen, H. J., Collier, P., Scott, E.: Ciprofloxacin in children and young adults with cystic fibrosis. 3rd Eur. Congr. Clin. Microbiol., The Hague, May 1987, 109 Abstr., 236.
Kurz, C. C., Marget, W., Harms, K., Bertele, R.-M. Vergleichende Untersuchung mit Ciprofloxacin und Ofloxacin im Kreuzversuch bei zystischer Fibrose. Fortschr. Antimikrob. Antineoplast. Chemother. 6–10 (1987) 2107–2113.
Schaad, U. B., Wedgwood, J., Kraemer, R.: Efficacy and safety of ciprofloxacin in pediatric patients with cystic fibrosis. 2nd Int. Symp. New Quinolones, Geneva, August 1988, 139.
Schaad, U. B., Wedgwood-Krucko, J. Efficacy and safety of ciprofloxacin in pediatric patients with cystic fibrosis. Rev. Infect. Dis. 11 (Suppl. 5) (1989) 25.
Schaad, U. B., Wedgwood-Krucko, J., Guenin, K., Buehlmann, U., Kraemer, R. Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin intravenously followed by oral ciprofloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 8 (1989) 858–865.
Schaad, U. B., Wedgwood, J., Terrier, F., Tschaeppeler, H., Vock, P.: Magnetic resonance imaging (MRI) examination of the knee in children with cystic fibrosis (CF) before and after a 3-month course of ciprofloxacin (CIP). 30th ICAAC Intersci. Conf. Antimicrob. Agents Chemother. 87, Atlanta, Oct. 1990, Abstr. 6.
Schaad, U. B., Stoupis, C., Wedgwood, J., Tschaeppeler, H., Vock, P. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin. Pediatr. Infect. Dis. J. 10 (1991) 723–729.
Rubio, T. T.: Ciprofloxacin in children with cystic fibrosis. Clinical and laboratory experience. 2nd Int. Symp. New Quinolones, Geneva, August 1988, 229.
Rubio, T. T. Ciprofloxacin in the treatment of Pseudomonas infection in children with cystic fibrosis. Diagn. Microbiol. Infect. Dis. 13 (1990) 153–155.
Rubio, T. T. Clinical and laboratory experience with ciprofloxacin in children two to sixteen years of age. Adv. Antimicrob. Antineoplast Chemother. 11 (1992) 151–154.
Baran, D., Dab, I., Pierard, D., Serruys, E. Prospective open efficacy and safety study of ciprofloxacin in the treatment of cystic-fibrosis patients with pulmonary infection. Scand. J. Gastroenterol. 23 (S 143) (1988) 172.
Bosso, J. A. Use of ciprofloxacin in cystic fibrosis patients. Am. J. Med. 87 (Suppl. 5 A) (1989) 123–127.
Strandvik, B., Hjelte, L., Lindblad, A., Ljungberg, B., Malmborg, A.-S., Nilsson-Ehle, I. Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection. Scand. J. Infect. Dis. 60 (1989) 84–88.
Desmyttere, S., Dab, I., Malfroot, A., Pierard, D., Desprechins, B.: Ciprofloxacin use in children with cystic fibrosis. 3rd Int. Symp. New Quinolones 8, Vancouver, July 1990, Abstr. 2.
Dab, I., Desmyttere, S., Malfroot, A. Repeated use of ciprofloxacin in a pediatric cystic fibrosis population. Adv. Antimicrob. Antineoplast Chemother. 11 (1992) 143–146.
Enenkel, S., Bender, S., Posselt, H. G.: Treatment with quinolones of pulmonaryPseudomonas aeruginosa infections in patients with cystic fibrosis. 3rd Int. Symp. New Quinolones 444, Vancouver, July 1990, Abstr. 359.
Kuhn, R. J., Palmejar, A., Kanga, J. F. Tolerability of ciprofloxacin in pediatric patients with cystic fibrosis. Adv. Antimicrob. Antineoplast Chemother. 11 (1992) 269–271.
Chysky, V., Kapila, K., Hullmann, R., Arcieri, G., Schacht, P., Echols, R. Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use. Emphasis on joint evaluation. Infection 19 (1991) 289–296.
Schaad, U. B., Wedgwood, J. Lack of quinolone-induced arthropathy in children. J. Antimicrob. Chemother. 30 (1992) 414–416.
Raeburn, J. A., Govan, J. R., Mccrae, W. M., Greening, A. P., Collier, P. S., Hodson, M. E., Goodchild, M. C. Ciprofloxacin therapy in cystic fibrosis. J. Antimicrob. Chemother. 20 (1987) 295–296.
Black, A., Redmond, A. O., Steen, H. J., Oborska, I. T. Tolerance and safety of ciprofloxacin in paediatric patients. J. Antimicrob. Chemother. 26 (Suppl. F) (1990) 25–29.
Bavdekar, A., Chaudhari, M., Bhave, S., Pandit, A. Ciprofloxacin in typhoid fever. Indian J. Pediatr. 58 (1991) 335–339.
Sen, S., Goyal, R. S., Rev, R. Ciprofloxacin in the management of multiple drug resistant typhoid fever. Indian Pediatr. 28 (1991) 417–419.
Arora, R. K., Gupta, A., Joshi, N. M., Kataria, V. K., Lall, P., Anand, A. C. Multidrug resistant typhoid fever: study of an outbreak in Calcutta. Indian Pediatr. 29 (1992) 61–66.
Cheesbrough, J. S., Mwema, F. I., Green, S. D., Tillotson, G. S. Quinolones in children with invasive salmonellosis. Lancet 338 (1991) 127.
Green, S. D., Lunga, F. M., Numbi, A., Cheesbrough, J. S., Tillotson, G. S. An open study of ciprofloxacin for the treatment of proven or suspected extraintestinal salmonellosis in African children: a preliminary report. Adv. Antimicrob. Antineoplast Chemother. 11 (1992) 181–187.
Dutta, P., Rasaily, R., Saha, M. R., Mitra, U., Bhattacharya, S. K., Bhattacharya, M. K., Lahiri, M. Ciprofloxacin for treatment of severe typhoid fever in children. Antimicrob. Agents Chemother. 37 (1993) 1197–1199.
Kiess, W., Haas, R., Marget, W. Chloramphenicol-resistantSalmonella tennessee osteomyelitis. Infection 12 (1984) 359.
Hoppe, J. E., Dopfer, R., Huber, S., Niethammer, D. Eradication ofSalmonella dublin in an immunodeficient child by combined use of ceftriaxone and ciprofloxacin after failure of either agent alone. Infection 17 (1989) 399–400.
Ragunathan, P. L., Potkins, D. V., Watson, J. G., Kearns, A. M., Carroll, A. Neonatal meningitis due toSalmonella typhimurium treated with ciprofloxacin. J. Antimicrob. Chemother. 26 (1990) 727–728.
Bhutta, Z. A., Faroqui, B. J., Sturm, A. W. Eradication of multiple drug resistantSalmonella paratyphi A causing meningitis with ciprofloxacin. J. Infect. 25 (1992) 215–219.
Lumbiganon, P., Pengsaa, K., Sookprance, T. Ciprofloxacin in neonates and its possible adverse effect on the teeth. Pediatr. Infect. Dis. J. 10 (1991) 619–620.
Goshen, S., Raas-Rothschild, A., Lang, R. Oral ciprofloxacin in the management of children with chronic suppurative otitis media without cholesteatoma. Adv. Antimicrob. Antineoplast Chemother. 11 (1992) 175–177.
Lang, R., Goshen, S., Raas-Rothschild, A., Raz, A., Ophir, D., Wolach, B., Berger, I. Oral ciprofloxacin in the management of chronic suppurative otitis media without cholesteatoma in children: preliminary experience in 21 children. Pediatr. Infect. Dis. J. 11 (1992) 925–929.
Bannon, M. J., Stutchfield, P. R., Weindling, A. M., Damjanovic, V. Ciprofloxacin in neonatalEnterobacter cloacae septicemia. Arch. Dis. Child. 64 (1989) 1388–1391.
Chapman, S. T., Speller, D. C. E., Reeves, D. S. Resistance to ciprofloxacin. Lancet i (1985) 39.
Newsom, S. W. B., Murphy, P., Warren, R. E., Matthews, J. Clinical studies with ciprofloxacin. Chemiotherapia 4 (Suppl. 2) (1985) 415–416.
Isaacs, D., Slack, M. P. E., Wilkinson, A. R., Westwood, A. Successful treatment ofPseudomonas ventriculitis with ciprofloxacin. J. Antimicrob. Chemother. 17 (1986) 535–538.
Bendig, J. W. A., Kyle, P. W., Giangrande, P. L. F., Samson, D. M., Azadian, B. S. Two neutropenic patients with multiple resistantPseudomonas aeruginosa septicaemia treated with ciprofloxacin. J. Royal Soc. Med. 80 (1987) 316–317.
Houwen, R. H., Bijleveld, C. M., de Vries-Hospers, H. G. Ciprofloxacin for cholangitis after hepatic portenterostomy. Lancet i (1987) 1367.
Lotti, T., Mirone, V., Imbimbo, C., Russo, A. Ciprofloxacin in the treatment of urinary tract infections. J. Int. Med. Res. 15 (1987) 240–244.
Martorana, G., Giberti, C., Pizzorno, R., Bonamini, A., Oneto, F., Curotto, A., Soro, O. Treatment of urinary tract infections with ciprofloxacin. Clin. Ther. 10 (1988) 516–520.
Dagan, R., Schlaeffer, F.: Parenteral fluoroquinolones in children with lifethreatening infections not responding to other antibiotics. 2nd Int. Symp. New Quinolones 136, Geneva, August 1988.
Dagan, R.;Schlaeffer, F., Einhorn, M. Parenteral fluoroquinolones in children with lifethreatening infections. Infection 18 (1990) 237–238.
Humphreys, H., Lovering, A., White, L. O., Williams, E. W. Flavobacterium meningosepticum infection, in a 32-day-old child on acute peritoneal dialysis, treated with ciprofloxacin. J. Antimicrob. Chemother. 23 (1989) 292–294.
Humphreys, H., Speller, D. C. E. Acute epididymo-orchitis caused byPseudomonas aeruginosa and treated with ciprofloxacin. J. Infection 19 (1989) 257–261.
Thomson, A. P. J., Damjanovic, V., Hart, C. A., Cooke, R. W. I. Bacillus licheniformis infection in a preterm neonate. Pediatr. Rev. Commun. 4 (1990) 147–149.
Hussey, G., Kibel, M., Parker, N. Ciprofloxacin treatment of multiple drug-resistant extrapulmonary tuberculosis in a child. Pediatr. Infect. Dis. 11 (1992) 408–409.
Kahana, L. M., Spino, M. Ciprofloxacin in patients with mycobacterial infections: experience in 15 patients. DICP Ann. Pharmacother. 25 (1991) 919–924.
Alfaham, M., Holt, M. E., Goodchild, M. C. Arthropathy in a patient with cystic fibrosis taking ciprofloxacin. Br. Med. J. 295 (1987) 699.
Jawad, A. S. M. Cystic fibrosis and drug-induced arthropathy. Br. J. Rheumatol. 28 (1989) 179–180.
Simpson, J., Watson, A. R., Mellersh, A., Nelson, C. S., Dodd, K. Typhoid fever, ciprofloxacin, and renal failure. Arch. Dis. Child 66 (1991) 1083–1084.
Harmon, T., Burkhart, G., Applebaum, H. Perforated pseudomembranous colitis in a breast-fed infant. J. Pediatr. Surg. 27 (6) (1992) 744–746.
Anand, A. C., Kataria, V. K., Singh, W., Chatterjee, S. K. Epidemic multiresistant enteric fever in Eastern India. Lancet 335 (1990) 352.
Giamarellou, H., Daphnis, E., Dendrinos, C., Daikos, G. K.: Experience with ciprofloxacin in the treatment of various infections caused mainly byPseudomonas aeruginosa. 6th Int. Symp. on Future Trends in Chemotherapy 73, Pisa, May 1984.
Giamarellou, H., Daphnis, E., Dendrinos, C., Petrikkos, G., Sahin, A., Daikos, G. K.: Experience with ciprofloxacin in the treatment of gram-negative infections includingP. aeruginosa. 4th Mediterranean Congr. of Chemotherapy, Rhodos, Oct. 1984, Abstr. 578.
Giamarellou, H., Daphnis, E., Galanakis, N., Dendrinos, C., Stephanou, J., Daikos, G. K.: Ciprofloxacin in the treatment of nosocomialPseudomonas aeruginosa infections. Int. Congr. Infect. Dis., Cairo, April 1985, Abstr. 264.
Giamarellou, H., Galanakis, N., Dendrinos, C., Stephanou, J., Daphnis, E., Daikos, G. K.: Evaluation of ciprofloxacin in “Difficult to Treat” infections. 2nd Eur. Congr. Clin. Microbiol., Brighton, GB, Sept. 1985, Abstr. S7/5.
Giamarellou, H., Galanakis, N., Stephanou, J., Daphnis, E., Daikos, G. K.: Clinical efficacy of ciprofloxacin in severe infections. 1st Int. Ciprofloxacin Workshop, Leverkusen, Nov. 1985, Proceedings 1986. Curr. Clin. Pract. Ser. 34 (eds.):Neu, H. C.: Excerpta Medica, Amsterdam, pp. 420–425.
Simmons, J. F., Cowley, C. E., Dozier, D. B., Galdini, A. M., Manes, M. R., Nungester, G. H., Schreeder, M. T., Strother, K. D., Chun, B. W. Clinical experience with ciprofloxacin: analysis of a multicenter study. Ala. Med. 58 (1989) 10–13.
Lopez, J. C., Cercenado, E., Rodriguez-Creixems, M., Romero, J., Garcia de la Torre, M., Bouza, E. Evaluacion de la ciprofloxacina en el tratamiento de infecciones bacteriana graves. Enferm. Infec. Microbiol. Clin. 7 (1989) 23–28.
Bianchi, W., Imbasciati, A., Mariani, L., Ohnmeiss, H. Results of clinical trials with ciprofloxacin in Italy. Chemioterapia 6 (1987) 445–450.
Schacht, P., Arcieri, G., Branolte, J., Bruck, H., Chysky, V. Eficacia y seguridad de ciprofloxacina datos clinicos recogidos a nivel mundial. Drugs of Today 24 (Suppl. 8) (1988) 49–62.
Schacht, P., Arcieri, G., Hullmann, R. Safety of oral ciprofloxacin. An update based on clinical trial results. Am. J. Med. 87 (Suppl. 5 A) (1989) 98–102.
Schacht, P., Arcieri, G., Hullmann, R.: Safety of oral ciprofloxacin — an update based on clinical trial results. In: Ciprofloxacin: major advances in intravenous and oral quinolone therapy. Naples, Florida (1989) p. 53, Abstr.
Reiter, C., Pfeiffer, M., Hullmann, R. Brief report: safety of ciprofloxacin based on phase IV studies (“Anwendungsbeobachtung”) in the Federal Republic of Germany. Am. J. Med. 87 (Suppl. 5 A) (1989) 103–106.
Schaad, U. B., Wedgwood-Krucko, J. Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity. Infection 15 (1987) 165–168.
Rumler, W., von Rohden, L.: Does nalidixic acid produce joint toxicity in childhood? Proceedings of the 15th Int. Congress of Chemotherapy, Istanbul, July 1987. In: Progr. Antimicrob. Anticancer Chemother. 1029–1031.
Adam, D. Use of quinolones in pediatric patients. Rev. Infect. Dis. 11 (Suppl. 5) (1989) 113–116.
Phillips, B. M., David, T. J. Pathogenesis and management of arthropathy in cystic fibrosis. J. Royal Soc. Med. 79 (Suppl. 12) (1986) 44–50.
Schaad, U. B. Role of the new quinolones in pediatric practice. Pediatr. Infect. Dis. J. 11 (1992) 1043–1046.
Scully, B. E., Nakatomi, M., Ores, C., Davidson, S., Neu, H. C. Ciprofloxacin therapy in cystic fibrosis. Am. J. Med. 82 (Suppl. 4 A) (1987) 196–201.
Cruciani, M., Di Perri, G., Concia, E., Bassetti, D., Navarra, A., Nespoli, L. Use of ciprofloxacin in childhood. J. Pediatr. 115 (1989) 1022–1023.
Douidar, S. M., Snodgrass, W. R. Potential role of fluoroquinolones in pediatric infections. Rev. Infect. Dis. 11 (1989) 878–889.
Grenier, B. Use of the new quinolones in cystic fibrosis. Rev. Infect. Dis. 11 (Suppl. 5) (1989) 1245–1252.
Aujard, Y. Quinolones in neonates. Adv. Antimicrob. Antineoplast Chemother. 11 (1992) 233–237.
Grenier, B. Use of fluoroquinolones in children. An overview. Adv. Antimicrob. Antineoplast Chemother. 11 (1992) 135–140.
Schaad, U. B. Toxicity of quinolones in pediatric patients. Adv. Antimicrob. Antineoplast Chemother. 11 (1992) 259–265.
Peltola, H., Väärälä, M., Renkonen O.-V., Neuvonen, P. J. Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children. Antimicrob. Agents Chemother. 36 (1992) 1086–1090.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kubin, R. Safety and efficacy of ciprofloxacin in paediatric patients — Review. Infection 21, 413–421 (1993). https://doi.org/10.1007/BF01728929
Issue Date:
DOI: https://doi.org/10.1007/BF01728929